Evidence map›Paper›PMID 29183160›Full record

Observational studyChronic respiratory disease2018

Daily spirometry in an acute exacerbation of adult cystic fibrosis patients.

Michael J Stephen, Alex Long, Chad Bonsall, Jeffrey B Hoag, Smita Shah, Dorothy Bisberg, Douglas Holsclaw, Laurie Varlotta, Stan Fiel, Doantrang Du and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Chronic respiratory disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Michael J Stephen1 Division of Pulmonary and Critical Care, Drexel University School of Medicine, Philadelphia, PA, USA.
Alex Long2 Drexel University School of Public Health, Philadelphia, PA, USA.
Chad Bonsall3 Division of Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey B Hoag1 Division of Pulmonary and Critical Care, Drexel University School of Medicine, Philadelphia, PA, USA.
Smita Shah4 Barnabas Health Medical Group, Saint Barnabas Medical Center, Pediatric Specialty Center, West Orange, NJ, USA.
Dorothy Bisberg4 Barnabas Health Medical Group, Saint Barnabas Medical Center, Pediatric Specialty Center, West Orange, NJ, USA.
Douglas Holsclaw3 Division of Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
Laurie Varlotta5 St Chrisophter's Hospital for Children, Philadelphia, PA, USA.
Stan Fiel6 Atlantic Health System, Morristown, NJ, USA.
Doantrang Du7 Monmouth Medical Center, Long Branch, NJ, USA.
Robert Zanni7 Monmouth Medical Center, Long Branch, NJ, USA.
Denis Hadjiliadis3 Division of Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
Drexel University · USUniversity of Pennsylvania · USMonmouth Medical Center · USSaint Barnabas Medical Center · USAtlantic Health System · USSt. Christopher's Hospital for Children · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

Indexed as

Administration, IntravenousAdultAnti-Bacterial AgentsCystic FibrosisFemaleForced Expiratory VolumeHumansMaleProspective StudiesSpirometrySurveys and QuestionnairesSymptom Flare UpTime FactorsYoung AdultAnti-Bacterial Agentsacute exacerbationCFQ-RCystic fibrosishome spirometryintravenous antibiotics

Identifiers

PMID29183160
PMCPMC6100161
OpenAlexW2768714162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.